Gilead has signed a deal with San Francisco biotech Nurix Therapeutics – a company focused on developing drugs that control levels of the enzyme ubiquitin E3 ligases which are responsible for the breakdown of proteins in human cells.
Dysregulated and/or mutated proteins play a central role in the development and progression of many human diseases. It is hoped that by controlling protein levels Nurix’s technologies will be able to tackle cancer and other challenging diseases.
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
